Robert Downey Jr on Celebrity Profiles
Robert Downey Jr On Celebrity Profiles – Robert John Downey, Jr. (born April 4, 1965) is an American actor. Downey made his screen debut in 1970, at the age of five, appearing in his father’s film Pound, and has worked consistently in film and television ever since. During the 1980s, he had roles in a series of coming of age films associated with the Brat Pack. His role in Less Than Zero (1987) was the first time Downey’s acting would be commended by critics. After Zero, Downey was cast in starring roles in bigger films, such as Air America (1990), Soapdish (1991), and Natural Born Killers (1994). He played Charlie Chaplin in the 1992 film Chaplin, for which he received an Academy Award nomination for Best Actor. Between 1996 and 2001, Downey was frequently arrested on drug-related charges. After being released from the California Substance Abuse Treatment Facility and State Prison in 2000, Downey joined the cast of the hit television series Ally McBeal playing the new love interest of Calista Flockhart’s title character. His performance was praised and received accolades, but his character was written out when Downey was fired after two drug arrests in late 2000 and early 2001. After one last stay in a court-ordered drug treatment program, Downey finally achieved lasting sobriety and his career began to take off again. He appeared in semi-independent films such as The Singing Detective (2003), Kiss Kiss Bang Bang (2005), and A Scanner Darkly (2006). He also had supporting roles in the mainstream films Gothika …
DELCATH ANNOUNCES JUNE 15, 2013 PDUFA GOAL DATE FOR NEW DRUG …
Filed under: drug treatment news 2013
NEW YORK, November 1, 2012 – Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 15, 2013, for substantive review of the Company's New …
Read more on Reuters
Firms Project 2013 BLA for Long-Acting Hemophilia A Therapy
Filed under: drug treatment news 2013
Biogen Idec and Swedish Orphan Biovitrum (SOBI) say they expect to file a BLA with FDA for their long-acting hemophilia A therapy during the first half of 2013, on the back of positive results from a Phase III study, which showed the recombinant …
Read more on Genetic Engineering News